A randomized phase III trial of IV carboplatin and paclitaxel × 3 courses followed by observation versus weekly maintenance low-dose paclitaxel in patients with early-stage ovarian carcinoma: a Gynecologic Oncology Group Study - Wikidata - wikimedia - TriplyDB

A randomized phase III trial of IV carboplatin and paclitaxel × 3 courses followed by observation versus weekly maintenance low-dose paclitaxel in patients with early-stage ovarian carcinoma: a Gynecologic Oncology Group Study

A randomized phase III trial of IV carboplatin and paclitaxel × 3 courses followed by observation versus weekly maintenance low-dose paclitaxel in patients with early-stage ovarian carcinoma: a Gynecologic Oncology Group Study

http://www.wikidata.org/entity/Q35033234

about

Adjuvant (post-surgery) chemotherapy for early stage epithelial ovarian cancer Adjuvant (post-surgery) chemotherapy for early stage epithelial ovarian cancer Maintenance chemotherapy for ovarian cancer Clinical outcome and prognostic factors of patients with early-stage epithelial ovarian cancer.Optimal treatment of early-stage ovarian cancer.Paclitaxel and Carboplatin (TC) Regimen for Ovarian Cancer.Optimizing molecular-targeted therapies in ovarian cancer: the renewed surge of interest in ovarian cancer biomarkers and cell signaling pathways.Systemic therapy for advanced soft tissue sarcomas: highlighting novel therapies and treatment approaches Morphologic and Molecular Characteristics of Mixed Epithelial Ovarian Cancers.Clinical utility of targeted treatments in the management of epithelial ovarian cancer.Clinical implications of using molecular diagnostics for ovarian cancers.S3-Guideline on Diagnostics, Therapy and Follow-up of Malignant Ovarian Tumours: Short version 1.0 - AWMF registration number: 032/035OL, June 2013.Web-based symptom management for women with recurrent ovarian cancer: a pilot randomized controlled trial of the WRITE Symptoms intervention.Palliative chemotherapy in carcinoma penis: Does platinum and taxane combination holds a promise?Re-visiting Hypersensitivity Reactions to Taxanes: A Comprehensive Review.Metronomics: towards personalized chemotherapy?Maintenance therapy in epithelial ovarian cancer: from chemotherapy to targeted agents.Frontline treatment of epithelial ovarian cancer.Survival benefit of patients with early-stage ovarian carcinoma treated with paclitaxel chemotherapeutic regimens.Removal of body surface area normalisation improves raw-measured glomerular filtration rate estimation by the Chronic Kidney Disease Epidemiology Collaboration equation and drug dosing in the obese.

P2860

Q24187061-2FB7968B-7419-47AC-BDB4-4E2122ABFAEF Q24201216-8BC62F2F-9AAA-42E9-BECD-97CBA6C9B5F9 Q24201758-BB6F9391-FF34-4A0C-816A-D86D02289D96 Q33618894-74B1C8C6-B840-4793-92F0-65D62F02A998 Q33683114-19929D57-BE20-467A-919F-B59012289C5A Q33774695-A6F8A2B7-DF17-4A83-B492-B98F085EB6D0 Q35837949-99B6C0FB-2763-4347-B143-CE6F2FA940A0 Q36144210-F39D4DF5-C440-4E30-844A-77606DC96E5A Q36157106-166F13D5-4F84-4E2D-8DE9-F0915BC3BE0D Q36171268-13CEA1E6-9FE9-42F5-A3F2-5882417D58C8 Q37332490-3101550A-FBCA-4B5E-8782-D7C55911B52F Q37383301-610FCDDA-1228-4100-83E4-A99219F591DE Q37598652-3588EA26-0E2D-41FB-9F11-E34994D8B252 Q37658110-6E270EAD-7898-4147-B876-29E63D9EACA1 Q38205153-3FF3EED3-ACB0-45B5-8D40-D3CE3044E716 Q38218923-040B6BC9-8668-43D6-AEC0-E1A0C58E5072 Q38222277-1EE8F7EB-9F1B-422E-B835-E0372DF2EFD2 Q38669746-76EE88A5-68BA-4FDA-86C5-FE6A9C7C0AFD Q47138082-86BE4174-A8E3-4388-85F9-7DB2C8F5FDAA Q48197002-3D03A106-BC4D-44B9-9864-66FFDF9A05A5

P2860

A randomized phase III trial of IV carboplatin and paclitaxel × 3 courses followed by observation versus weekly maintenance low-dose paclitaxel in patients with early-stage ovarian carcinoma: a Gynecologic Oncology Group Study

http://www.wikidata.org/entity/Q35033234

description

2011 nî lūn-bûn

@nan

2011 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

A randomized phase III trial o ...... necologic Oncology Group Study

@ast

A randomized phase III trial o ...... necologic Oncology Group Study

@en

type

label

A randomized phase III trial o ...... necologic Oncology Group Study

@ast

A randomized phase III trial o ...... necologic Oncology Group Study

@en

prefLabel

A randomized phase III trial o ...... necologic Oncology Group Study

@ast

A randomized phase III trial o ...... necologic Oncology Group Study

@en

P1433

Q35033234-1B9DB0D5-2563-47BE-9FCB-D3A7DFCEFCC1

P1476

Q35033234-FBA76BDB-6AD6-4361-BEE5-03FB7C0DA0A9

P2093

Q35033234-0E08B7AF-C233-477B-828D-44017B347D96

Q35033234-218272B8-116A-47E4-8FA6-F067B55910D4

Q35033234-29808F36-1249-4513-B7BE-2434D6AEB41E

Q35033234-35FFBD32-BE9A-4F3C-8BD4-11D1AB63F8EE

Q35033234-C079EE7D-0135-439B-B621-CB15C39E4C42

Q35033234-DC9C6A0B-C7FB-49BE-A1AA-BA7A775B7FE8

Q35033234-E06A5998-21E9-48E5-9D8D-AD85B9C6EDB4

Q35033234-E3F45E8E-CDC1-4371-ABD2-83BF224ABDDA

Q35033234-F7C4159C-638C-431E-A27B-671E50455131

P2860

Q35033234-212FE007-BBDC-49EB-807E-5862A176422F

Q35033234-2491DAC6-1633-4E78-A64F-B4154EA617DC

Q35033234-28A9DD79-FE8D-4933-BD78-5A01B74453C2

Q35033234-3BA52337-935F-48DB-96FF-BEA75EFD8DDF

Q35033234-55E59843-A678-4F52-88C9-42F49B091BCB

Q35033234-6B7B1B38-B523-4FD3-B72B-969E19549997

Q35033234-7B414B4E-C23D-4C50-8D27-A9A3A3531BE8

Q35033234-7C4D4C62-A0E8-41A6-A999-0B4E625CC420

Q35033234-7CDA18F1-B511-45D7-8AE0-8550A16BD75A

Q35033234-7E31E3FD-A327-4081-AAB8-BB9ED7FA0A07

P304

Q35033234-FBF9F613-A4F7-434B-B8D3-AC510FAEF421

P31

Q35033234-16C33FCB-67B0-4FAD-AED0-01DEAB38943E

P356

Q35033234-87ECA055-F24E-4D13-846C-5ECABDE47D0F

P407

Q35033234-49520433-4807-4942-A3DB-9684619DE106

P433

Q35033234-C15A94C8-0730-4B65-8690-3DBF1C5A8DDE

P478

Q35033234-177DF071-5542-442D-B7B0-024C21BB1EC3

P50

Q35033234-3E293CF9-9FA3-478E-9709-02BEACC79E40

P577

Q35033234-D6118CC2-1B0F-4CFF-9585-A8BF5B69F811

P5875

Q35033234-195A98F4-3CD0-438A-B38C-F5EA45509CE2

P698

Q35033234-D3A5B64F-6350-410F-A0C0-E9F73B646827

P921

Q35033234-884AD1C1-19B6-4C26-B167-C2A7A65C740F

P932

Q35033234-8E3A64D7-C7B3-4839-94A7-275334850A9A

P356

J.YGYNO.2011.03.013

P1433

Gynecologic Oncology

P1476

A randomized phase III trial o ...... necologic Oncology Group Study

@en

P2093

Bradley J Monk

http://www.w3.org/2001/XMLSchema#string

Elise C Kohn

http://www.w3.org/2001/XMLSchema#string

Helen Michael

http://www.w3.org/2001/XMLSchema#string

Koen Degeest

http://www.w3.org/2001/XMLSchema#string

Mark F Brady

http://www.w3.org/2001/XMLSchema#string

Masamichi Hiura

http://www.w3.org/2001/XMLSchema#string

Parviz Hanjani

http://www.w3.org/2001/XMLSchema#string

Robert S Mannel

http://www.w3.org/2001/XMLSchema#string

Roger Lee

http://www.w3.org/2001/XMLSchema#string

P2860

Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: a Phase III Trial of the Gynecologic Cancer Intergroup.

Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study.

International Collaborative Ovarian Neoplasm trial 1 and Adjuvant ChemoTherapy In Ovarian Neoplasm trial: two parallel randomized phase III trials of adjuvant chemotherapy in patients with early-stage ovarian carcinoma.

2004 consensus statements on the management of ovarian cancer: final document of the 3rd International Gynecologic Cancer Intergroup Ovarian Cancer Consensus Conference (GCIG OCCC 2004).

Adjuvant therapy in stage I and stage II epithelial ovarian cancer. Results of two prospective randomized trials.

Evaluation of survival data and two new rank order statistics arising in its consideration.

Adjuvant treatment for early ovarian cancer: a randomized phase III trial of intraperitoneal 32P or intravenous cyclophosphamide and cisplatin--a gynecologic oncology group study.

Tumor angiogenesis in advanced stage ovarian carcinoma.

Pathogenesis of ovarian cancer: lessons from morphology and molecular biology and their clinical implications.

Genomic analysis of epithelial ovarian cancer.

P304

89-94

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.YGYNO.2011.03.013

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

122

http://www.w3.org/2001/XMLSchema#string

P50

P577

2011-05-06T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51086229

http://www.w3.org/2001/XMLSchema#string

P698

21529904

http://www.w3.org/2001/XMLSchema#string

P921

phase III clinical trial

P932

3110746

http://www.w3.org/2001/XMLSchema#string